Immuneering Co. (NASDAQ:IMRX) Shares Sold by Millennium Management LLC

Millennium Management LLC lowered its stake in shares of Immuneering Co. (NASDAQ:IMRX - Free Report) by 58.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 102,936 shares of the company's stock after selling 143,334 shares during the period. Millennium Management LLC owned about 0.33% of Immuneering worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. HighTower Advisors LLC boosted its position in Immuneering by 33.7% during the fourth quarter. HighTower Advisors LLC now owns 71,360 shares of the company's stock worth $157,000 after purchasing an additional 18,000 shares in the last quarter. XTX Topco Ltd grew its position in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after purchasing an additional 20,871 shares during the period. Marshall Wace LLP purchased a new stake in shares of Immuneering in the fourth quarter valued at $47,000. Bridgeway Capital Management LLC increased its stake in Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after purchasing an additional 22,400 shares during the last quarter. Finally, First Manhattan CO. LLC. acquired a new position in shares of Immuneering during the 4th quarter valued at about $71,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IMRX has been the topic of several research reports. Oppenheimer cut their target price on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of Immuneering in a research report on Thursday, June 5th. Finally, Chardan Capital restated a "buy" rating and set a $13.00 target price on shares of Immuneering in a research note on Tuesday, May 6th.

Immuneering Trading Down 7.5%

NASDAQ IMRX traded down $0.16 on Thursday, hitting $1.96. 295,807 shares of the stock traded hands, compared to its average volume of 2,346,947. The company has a market capitalization of $70.53 million, a P/E ratio of -0.99 and a beta of 0.01. Immuneering Co. has a twelve month low of $1.00 and a twelve month high of $3.83. The stock has a 50-day moving average of $1.48 and a 200 day moving average of $1.74.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). As a group, equities research analysts expect that Immuneering Co. will post -1.86 earnings per share for the current year.

Immuneering Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.